🚀 VC round data is live in beta, check it out!
- Public Comps
- Harvard Apparatus
Harvard Apparatus Valuation Multiples
Discover revenue and EBITDA valuation multiples for Harvard Apparatus and similar public comparables like AnteoTech, Proteomics, Bio-Works Technologies, Genoway and more.
Harvard Apparatus Overview
About Harvard Apparatus
Harvard Apparatus Regenerative Technology Inc is a clinical-stage biotechnology company developing regenerative-medicine treatments for disorders of the gastrointestinal system and the airway resulting from cancer, trauma, or birth defects. The company's technology is based on its proprietary cell-therapy platform that uses a patient’s stem cells to regenerate and restore function to damaged organs.
Founded
2012
HQ

Employees
8
Website
Sectors
Financials (FY)
EV
$26M
Harvard Apparatus Financials
Harvard Apparatus reported last fiscal year revenue of $704K and negative EBITDA of ($7M).
In the same fiscal year, Harvard Apparatus generated $58K in gross profit, ($7M) in EBITDA losses, and had net loss of ($7M).
Revenue (LTM)
Harvard Apparatus P&L
In the most recent fiscal year, Harvard Apparatus reported revenue of $704K and EBITDA of ($7M).
Harvard Apparatus expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $704K | XXX | XXX | XXX |
| Gross Profit | — | XXX | $58K | XXX | XXX | XXX |
| Gross Margin | — | XXX | 8% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($7M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (960%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (982%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($7M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (976%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Harvard Apparatus Stock Performance
Harvard Apparatus has current market cap of $28M, and enterprise value of $26M.
Market Cap Evolution
Harvard Apparatus' stock price is $1.57.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $26M | $28M | 0.0% | XXX | XXX | XXX | $-0.39 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialHarvard Apparatus Valuation Multiples
Harvard Apparatus trades at 37.6x EV/Revenue multiple, and (3.9x) EV/EBITDA.
EV / Revenue (LTM)
Harvard Apparatus Financial Valuation Multiples
As of April 19, 2026, Harvard Apparatus has market cap of $28M and EV of $26M.
Equity research analysts estimate Harvard Apparatus' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Harvard Apparatus has a P/E ratio of (4.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $28M | XXX | $28M | XXX | XXX | XXX |
| EV (current) | $26M | XXX | $26M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 37.6x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (3.9x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (3.8x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 456.6x | XXX | XXX | XXX |
| P/E | — | XXX | (4.0x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (6.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Harvard Apparatus Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Harvard Apparatus Margins & Growth Rates
Harvard Apparatus' revenue in the last fiscal year grew by 64%.
Harvard Apparatus' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.9M for the same period.
Harvard Apparatus Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 64% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (960%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (10%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 10% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 604% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 377% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 990% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Harvard Apparatus Public Comps
See public comps and valuation multiples for other Life Sciences Tools comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Harvard Apparatus | XXX | XXX | XXX | XXX | XXX | XXX |
| AnteoTech | XXX | XXX | XXX | XXX | XXX | XXX |
| Proteomics | XXX | XXX | XXX | XXX | XXX | XXX |
| Bio-Works Technologies | XXX | XXX | XXX | XXX | XXX | XXX |
| Genoway | XXX | XXX | XXX | XXX | XXX | XXX |
| Biohit | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Harvard Apparatus M&A Activity
Harvard Apparatus acquired XXX companies to date.
Last acquisition by Harvard Apparatus was on XXXXXXXX, XXXXX. Harvard Apparatus acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Harvard Apparatus
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialHarvard Apparatus Investment Activity
Harvard Apparatus invested in XXX companies to date.
Harvard Apparatus made its latest investment on XXXXXXXX, XXXXX. Harvard Apparatus invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Harvard Apparatus
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Harvard Apparatus
| When was Harvard Apparatus founded? | Harvard Apparatus was founded in 2012. |
| Where is Harvard Apparatus headquartered? | Harvard Apparatus is headquartered in United States. |
| How many employees does Harvard Apparatus have? | As of today, Harvard Apparatus has over 8 employees. |
| Is Harvard Apparatus publicly listed? | Yes, Harvard Apparatus is a public company listed on OTC Pink Sheets. |
| What is the stock symbol of Harvard Apparatus? | Harvard Apparatus trades under HRGN ticker. |
| When did Harvard Apparatus go public? | Harvard Apparatus went public in 2013. |
| Who are competitors of Harvard Apparatus? | Harvard Apparatus main competitors are AnteoTech, Proteomics, Bio-Works Technologies, Genoway. |
| What is the current market cap of Harvard Apparatus? | Harvard Apparatus' current market cap is $28M. |
| What is the current revenue of Harvard Apparatus? | Harvard Apparatus' last fiscal year revenue is $704K. |
| What is the current EV/Revenue multiple of Harvard Apparatus? | Current revenue multiple of Harvard Apparatus is 37.6x. |
| Is Harvard Apparatus profitable? | No, Harvard Apparatus is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.